Announcements Trials
Browse Landscape

Phase

Phase 2 107Phase 1 39Phase 1/2 29Phase NA 24Phase 3 19Phase 2/3 5Phase 4 4Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 16Other hematologic neoplasm 15Lymphoid 8Plasma cell 4Other neoplasm 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Venous Thromboembolism 2Thrombosis 2Thrombocytopenia 2Primary Myelofibrosis 2Lymphoma 2Anemia, Aplastic 2Venous Thrombosis 1Thromboembolism 1Thrombocytosis 1Pulmonary Embolism 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Genetic Diseases, Inborn 1Cytopenia 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1Anemia, Hemolytic, Autoimmune 1Anemia 1

Interventions

daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Myelodysplastic Syndromes × Classical hematology × Clear all
NCT06398457 2025-09-26

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Recruiting
8 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡